Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zarnestra and Velcade in relapsed multiple myeloma
NCT00361088Phase 2Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Aug 2005
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tipifarnib in multiple myeloma (MM) (2 arms), sponsored by Moffitt Cancer Center. Primary endpoints: Dose Limiting Toxicity at 6 months, Maximum Tolerated Dose at 6 months and 2 more. Started Aug 2005; status: terminated.
02
Drugs
tipifarnib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00361088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00361088.